It was reported that MeCP2 (methyl-CpG binding protein 2) could promote ubiquitination-dependent p53 degradation and further inhibit RPL5/RPL11 transcription, which eventually facilitates the carcinogenesis of breast cancer (43). Here, MECP2 is linked to breast carcinoma.